Potential vaccine Novavax will complete its Phase 3 clinical trial in the UK. If the vaccines are proven to be safe and effective they could be delivered to the UK by the middle of next year. There are now plans to manufacture the COVID-19 vaccine in the UK and gain access to 60 million doses.
The UK will also co-fund a global clinical trial with the Janssen Pharmaceutical Companies of Johnson & Johnson which will account for the other 30 million doses.
Priority would be given to groups such as health and social care workers and those with conditions that put them at higher risk from the coronavirus.
With the two new deals, the UK has secured access to six vaccine candidates.
US drug developer Novavax Inc said on Friday the UK would buy 60 million doses of its coronavirus vaccine candidate, NVX-CoV2373, for a phase 3 clinical trial in the country.
Coronavirus BREAKTHROUGH: UK secures early access to 90 million doses of COVID-19 vaccine candidates
The company and the UK government will collaborate for the trial to assess the efficacy of the vaccine in the UK population, Novavax said in a statement, but did not disclose any financial details of the agreement.
The trial will be a study in about 9,000 adults between 18 years and 85 years of age.
Novavax would partner with Fujifilm Diosynth Biotechnologies for manufacturing the antigen component of its COVID-19 vaccine candidate in the UK, it added.
A vaccine would be a massive boost in the fight against COVID0-19
The company is also gearing up to deliver 100 million doses to the United States by January after it was awarded $ 1.6 billion to cover testing and manufacturing of its potential vaccine in the country.
Novavax has received $ 2 billion in funding so far for its coronavirus vaccine, including $ 384 million from the Coalition for Epidemic Preparedness Innovations (CEPI).
The NVX-CoV2373 doses will be supplied to the UK beginning as early as the first quarter of 2021, while phase 3 trial is expected to begin in the third quarter of this year, the company said.
Russia’s President Vladimir Putin
Xi Jinping’s China is also developing a vaccine
The Fujifilm Diosynth Biotechnologies site in the UK is expected to produce about 180 million doses annually, it added.
The United States and United Kingdom are leading a rush to strike deals with drugmakers to reserve supplies of experimental coronavirus vaccines, as the race to develop a safe and effective vaccine reaches the final stages of testing.
There are currently no approved vaccines for COVID-19, with over 25 candidates being studied in humans.
In an early-stage trial, Novavax’s vaccine candidate, NVX-CoV2373, has produced higher levels of antibodies in healthy volunteers after two doses than those found in recovered COVID-19 patients and the vaccine was “well tolerated” overall.
The coronavirus strain which causes COVID-19
We believe that Novavax has a highly innovative vaccine that could be the first in its class of protein-based vaccine options.
Kate Bingham, Chair of the UK Government’s Vaccines Taskforce, said: “It is encouraging that Novavax’ recent clinical data shows their vaccine triggers an immune response greater than that in patients who have recovered from the disease.
“We believe that Novavax has a highly innovative vaccine that could be the first in its class of protein-based vaccine options.
“We are happy to partner with them and global organisations such as CEPI to further our mutual commitments to ensure global access to the vaccine.”
Ms Bingham said the UK had also signed a separate vaccine deal with drug manufacturers and Johnson & Johnson.
A history of vaccines
Paul Found, Chief Operating Officer, FUJIFILM Diosynth Biotechnologies, UK site, said: “To change the course of the pandemic, FUJIFILM Diosynth Biotechnologies is excited to expand our partnership with Novavax to manufacture their COVID-19 vaccine candidate at our UK site.
“We are honored to support the UK government and Novavax with the shared goal of delivering a safe and effective vaccine to the British people.”
Stanley C Erck, President and Chief Executive Officer of Novavax, said: “Our Phase 3 clinical trial in the UK will be a critical component to assess the efficacy of NVX-CoV2373, which in a Phase 1 trial has already demonstrated to be generally well-tolerated and to elicit robust antibody responses.
“We are also delighted to expand our collaboration with FUJIFILM Diosynth Biotechnologies to manufacture our antigen at its UK site.”
The race to develop a vaccine is arguably the most hotly contested in the history of pharmaceutical technology.
Earlier this week, Russian President Vladimir Putin claimed his country was ready to deploy its own vaccine, which had already been administered to his own daughter.
Meanwhikle, today researchers announced a coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials.
MORE TO FOLLOW…
Source Daily Express :: UK Feed